teniposide, VM-26
teniposide, VM-26 information and resources from the National Cancer Institute
Vumon
In combination with other approved anticancer agents for induction therapy in patients with refractory childhood acute lymphoblastic leukemia (all).
Bristol-Myers Squibb Jul 14 1992
teniposide, VM-26 -->
Home
|
About
|
Search topics
|
Cancers
|
Treatment
|
Medications
Onconews provides free news and resources on cancer-related topics.
Copyright onconews.org 2005-2006.
All Rights Reserved.
Web
onconews.org
